

Title

1 Resolution of blood RNA signatures fails to discriminate sputum culture status after eight weeks of tuberculosis
2 treatment.

Authors

3 Claire J Calderwood^{*1,2}, Alvaro Sanchez Martinez^{*1}, James Greenan-Barrett³, Blanché Oguti¹, Jennifer Roe¹,
4 Rishi Gupta¹, Adrian R Martineau^{§4} Mahdad Noursadeghi^{§1}

5 ^{*}Contributed equally. [§]Co-senior authors.

Affiliations

- 6 1. Division of Infection and Immunity, University College London, London, United Kingdom
- 7 2. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, United
8 Kingdom
- 9 3. Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London,
10 United Kingdom
- 11 4. Blizard Institute, Queen Mary University of London, London, United Kingdom

Corresponding authors

12 Mahdad Noursadeghi (m.noursadeghi@ucl.ac.uk) and Adrian Martineau (a.martineau@qmul.ac.uk).

Key words:

13 Tuberculosis, Blood RNA signatures, CRP, Treatment response.

Research in context

14 ***Evidence before this study***

15 We performed a systematic review, using comprehensive terms for “tuberculosis”, “transcriptional” and
16 “biomarker” with no language or date restrictions in Medline on October 4, 2023. Many studies have described
17 normalisation of blood RNA signatures during the course of tuberculosis treatment. Five studies have
18 evaluated blood RNA signatures as a test of microbiological cure after completion of 6 months of treatment.
19 However, there is growing interest in their application as a test of cure to support shortened treatment
20 regimens. The performance of one blood RNA signature has been reported to provide modest discrimination
21 of contemporary sputum culture status at 8 weeks of treatment among HIV co-infected patients with recurrent
22 tuberculosis. We found no reports of whether these findings are generalisable to other blood RNA signatures
23 or to HIV negative patients with their first episode of tuberculosis, who are most likely to be candidates for
24 shortened treatment regimens.

25 ***Added value of this study***

26 To our knowledge, we provide the first evaluation and comparison of multiple blood RNA signatures of
27 tuberculosis for discrimination of microbiological cure after 8 weeks of tuberculosis therapy among HIV
28 negative patients. 12 previously validated blood RNA signatures of tuberculosis identified by systematic review
29 underwent head-to-head evaluation, alongside blood C-reactive protein measurement as an alternative
30 biomarker of disease, to determine whether they discriminated contemporary sputum culture status after 8
31 weeks of treatment among 44 HIV negative patients with smear-positive drug-sensitive tuberculosis enrolled
32 to a previously reported randomised controlled trial of adjunctive vitamin D therapy. None of the blood RNA
33 signatures showed statistically significant discrimination of contemporary sputum culture status after 8 weeks
34 tuberculosis treatment, or quantitative relationships with sputum bacterial load among sputum culture positive
35 cases. Importantly, most sputum culture positive cases at this time point, showed contemporary blood RNA
36 signature scores within the normal range.

37 ***Implications of all the available evidence***

38 Assuming that microbiological cure is a pre-requisite for early cessation of antimicrobial treatment for
39 tuberculosis, the current repertoire of blood RNA signatures of tuberculosis does not provide host response
40 surrogates of microbiological cure to support introduction of 8-week treatment regimens. Therefore, there is a
41 need for further discovery and validation of new biomarkers to support risk stratification for truncated therapy
42 both for research and clinical practice applications. The lack of association between blood transcriptomic
43 signatures and sputum culture status after 8 weeks of treatment suggests the existence of microbial sub-
44 populations that do not trigger a host response. Whether this reflects a state of latency or bacterial persistence
45 in immune privileged compartments requires further investigation.

Summary

46 **Background**

47 There is concerted effort to reduce the burden of 6 months antimicrobial treatment for tuberculosis (TB). Early
48 treatment cessation at 8 weeks is effective for most but incurs increased risk of disease relapse. We tested
49 the hypothesis that blood RNA signatures of TB disease or C-reactive protein (CRP) measurements
50 discriminate microbiological cure after 8 weeks of treatment, as a pre-requisite for a biomarker to stratify risk
51 of relapse.

52 **Methods**

53 We identified blood RNA signatures of TB disease or cure by systematic review. We evaluated CRP
54 measurements and blood RNA signatures that could be reproduced in genome-wide transcriptomic data from
55 a previously reported longitudinal dataset in pulmonary TB, spanning samples collected pre-treatment, at 2
56 and 8 weeks of treatment, and after 2 years of follow up. In our primary analysis, we tested discrimination of
57 sputum culture positivity at 8 weeks by contemporary blood RNA and CRP measurements using area under
58 the receiver operating characteristic curve (AUROC) analysis. In secondary analyses, we tested the
59 relationship between biomarker measurements and time to culture positivity as a surrogate for bacterial load
60 in sputum culture positive cases at 8 weeks, and discrimination of sputum culture status at 8 weeks by
61 biomarker measurements at any other time point.

62 **Findings**

63 We evaluated 12 blood RNA signatures. Blood RNA signature scores normalised over time from TB treatment
64 initiation. 11/44 cases with available blood RNA, CRP and sputum culture results, were sputum culture positive
65 at 8 weeks of treatment. None of the 12 blood RNA signature scores tested achieved statistically significant
66 discrimination between sputum culture-positive vs. negative patients at this time point, with AUROC point
67 estimates of 0.48-0.61. CRP achieved the best AUROC of 0.69 (95% confidence interval 0.52-0.87). None of
68 the contemporary biomarker measurements correlated with bacterial load, and no measurements pre-
69 treatment or at 2 weeks discriminated sputum culture status at 8 weeks.

70 **Interpretation**

71 The current repertoire of blood RNA signatures of TB and CRP will not provide host response surrogates of
72 microbiological cure to support cessation of TB treatment at 8 weeks. Decoupling of blood transcriptional host-
73 response from the presence of viable bacteria is indicative of subpopulations of *Mycobacterium tuberculosis*
74 able to colonise the respiratory tract without triggering a detectable immune response.

Introduction

75 Standard treatment for drug-sensitive pulmonary tuberculosis (TB) involves at least six months of combination
76 antimicrobial treatment, which exceed 95% cure rates in optimal settings¹. Clinical trials of antimicrobial
77 treatment regimens have reported over 85% people achieving cure with 3-4 months of treatment²⁻⁶. These
78 underpinned a novel approach to reduce the treatment burden by using boosted 8-week antimicrobial
79 regimens, followed by extended treatment for persistent disease, monitoring after treatment and retreatment
80 for relapse. This approach achieved equivalent outcomes to standard care at 96 weeks with a 12% non-
81 inferiority margin⁷. However, approximately 20% of people experienced relapse during the follow-up period.
82 Effective approaches to stratify individual-level risk of relapse at the end of shortened TB treatment regimens
83 are required to enable implementation of these approaches in clinical practice.

84 There has been sustained interest in blood RNA biomarkers of TB as triage tests for symptomatic TB⁸⁻¹⁰, and
85 for pre-symptomatic or incipient TB¹¹. Taken together with the observation that their levels can change from
86 the first week of therapy and normalise with treatment^{12,13}, this piqued interest in their application to predict
87 clinical outcomes or as a test of cure, with potential to provide greater sensitivity than resolution of symptoms,
88 and overcome the difficulties in obtaining sputum for microbiological testing. A number of studies have reported
89 that these biomarkers discriminate contemporary microbiological treatment failure at the end of standard 6-
90 month treatment regimens^{12,14-16}. Only one study has evaluated the performance of an 11-gene (Darboe11)
91 signature to discriminate contemporary microbiological cure before completion of 6 months treatment, as a
92 pre-requisite for their potential utility to stratify risk of relapse following truncated treatment regimens. This
93 showed statistically significant, but modest discrimination of early and late sputum culture conversion after 8
94 weeks treatment with point estimate for area under the receiver operating characteristic curve (AUROC) of
95 0.73, but was limited to HIV co-infected individuals with recurrent TB¹⁷. It is not known whether this finding is
96 generalisable to other gene signatures or to HIV negative patients with their first episode of TB that may be
97 candidates for shortened treatment regimens. We addressed this knowledge gap by testing the hypothesis
98 that blood RNA biomarkers of TB discriminate early microbiological treatment response (8-week sputum
99 culture conversion) among people with pulmonary TB by undertaking a comparative analysis of candidate
100 signatures, identified by systematic review, in a longitudinal clinical trial dataset¹⁸. We and others have shown
101 that the long-established blood biomarker of inflammation, C-reactive protein (CRP) has comparable
102 performance to blood RNA biomarkers of TB as triage test for disease^{19,20}. Therefore, we also evaluated CRP
103 as a test of microbiological cure/response to treatment at 8-weeks alongside our analysis of blood RNA
104 biomarkers.

Methods

105 ***Study approvals***

106 Blood sampling for transcriptomic analyses performed in the present study was approved by UK National
107 Research Ethics services (reference number: 06/Q0605/83). All subjects provided written informed consent.

108 ***Selection of biomarker signatures***

109 We updated a previous systematic search (on 14/02/2023) to identify candidate blood RNA biomarkers, using
110 the same databases and search strategy as described previously⁸ (Supplementary Methods, Supplementary
111 File 1). All records identified by the original and updated searches were sifted in duplicate (ASM, BO, CC) to

112 reflect updated inclusion criteria. In the current review, we included articles that described discovery of at least
113 one concise whole blood mRNA signature for the purpose of assessing the response to TB treatment, as well
114 as those for diagnosis of active or incipient TB. Only signatures which had been validated in at least one
115 separate dataset and were fully reproducible through a published calculation or regression equation were
116 included. Signatures comprised of multiple genes are referred to as the surname of the first author of the
117 corresponding publication, suffixed by the number of constituent genes.

118 ***Study cohort and biomarker measurements***

119 Genome-wide blood transcriptomic data were obtained using cDNA microarrays, as previously described²¹, in
120 a subset of 46 people (Supplementary Table 1) with smear and culture-positive drug-sensitive pulmonary TB
121 enrolled to a randomised controlled trial of adjunctive vitamin D therapy (AdjuVIT)¹⁸. We included a random
122 sample from participants in whom sputum culture results were available at eight weeks post-treatment, and
123 longitudinal blood RNA samples were available pre-treatment and any of two weeks, eight weeks or two years
124 post-treatment (Supplementary Figure 1). Sputum cultures and CRP measurements at eight weeks post-
125 treatment were performed as part of the study protocol in the original trial. CRP levels after eight weeks
126 treatment were previously reported, stratified by treatment arm and participant vitamin D receptor genotype²²,
127 but not previously related to 8-week sputum culture status.

128 ***Data Analysis***

129 Analyses were performed using R (version 3.6.1). Blood RNA signature scores were calculated using the
130 authors' described methods. Blood RNA signatures with more than 20% of constituent genes missing, because
131 they were not represented among protein-coding genes within the microarray dataset, were excluded
132 (Supplementary Table 1). Signature scores were scaled by Z-scores standardised to the mean and standard
133 deviation of measurements from a subset of participants with sustained cure two years after treatment
134 completion (N=31). Receiver operating characteristic curve (ROC) analysis using the pRoc package evaluated
135 two-class discrimination, with pairwise comparisons of ROC curves performed using the DeLong method²³.
136 Sensitivity and specificity were calculated at the maximum Youden index of the ROC curve, and pre-specified
137 thresholds of a Z-score of 2 (Z₂) for blood RNA signatures and 5 mg/L for CRP. The primary analysis focussed
138 on biomarker discrimination area under the ROC curve (AUROC) of sputum culture status at 8 weeks of
139 treatment. In addition, we undertook secondary analyses to test the hypothesis that biomarker levels at 8
140 weeks correlated with quantitative bacterial load in sputum culture positive individuals at 8 weeks of treatment,
141 and to evaluate discrimination of 8 week sputum culture status by biomarker measurements in the preceding
142 time points (pre-treatment, 2 weeks and 4 weeks).

143 The inclusion criteria for selection of gene signatures in the present systematic review excluded the Darboe11
144 signature because this required re-derivation by a support vector machine learning model. However, we
145 recently showed that the average expression of these genes performs as well as original SVM derived
146 signature²⁰. Since this signature had been previously reported to discriminate 8-week sputum culture
147 conversion, we included the average signature score as a supplementary analysis in the present study.

148 ***Data availability***

149 The microarray data presented in this study will be made available in an open-access public repository at the
150 time of peer-reviewed publication.

151 **Statistical power**

152 The sample size was determined by the number of cases from the AdjuVIT trial for which blood RNA, CRP
153 and sputum culture results were available. We evaluated the power to identify statistically significant ($p < 0.05$)
154 discrimination of sputum culture positive and culture negative cases from total sample size $N=44$ stratified by
155 ratio of positive:negative control cases and AUROC (PASS2022 software) (Supplementary Figure 2).

Results

156 **Resolution of candidate blood RNA biomarkers of TB with curative treatment**

157 1133 publications identified by systematic review yielded 38 studies and 49 blood RNA signatures of TB that
158 met the criteria for inclusion. 37 of the 49 blood RNA signatures were excluded from further analysis either as
159 they required model recreation ($n=16$), because there were signatures of lesser accuracy within the same
160 study ($n=12$), due to the signature assessing an incorrect indication ($n=3$), or due to missing genes ($n=6$). 12
161 blood RNA signatures were included in downstream analyses. (Supplementary Figure 3, Supplementary Table
162 2, Supplementary File 1).

163 Blood RNA signature scores normalised over time from TB treatment initiation (Figure 1). Consistent with their
164 identification as biomarkers of active TB disease, most of these showed high classification accuracy for
165 discriminating between pre-treatment measurements and 2-year post-treatment measurements (AUROC
166 range 0.67–0.99, Supplementary Figure 4, Supplementary Table 3). At the prespecified Z2 threshold which
167 approximates specificity to 98% by virtue of standardising biomarker scores using the distribution of 2-year
168 post-treatment scores, the blood RNA signatures achieved sensitivity point estimates of 20-98% for
169 identification of TB disease represented by the pre-treatment samples. A statistically significant reduction in
170 the distribution of blood RNA signature scores compared to pre-treatment baseline measurements, was
171 evident at 2 weeks for one single gene signature (ADM), and for all other signatures by 8 weeks treatment.

172 **Biomarker discrimination of sputum culture status at 8 weeks post-treatment**

173 11 of 44 patients with blood RNA data available at 8 weeks of treatment had contemporary Mtb culture positive
174 sputum (Supplementary Figure 1). In the primary analysis, this case mix provided 80% power to discriminate
175 culture positive and negative cases with AUROC > 0.75 (Supplementary Figure 2). None of the 12 blood RNA
176 signature scores tested achieved statistically significant discrimination between patients by sputum culture
177 status at this time point, with AUROC point estimates of 0.48-0.61. CRP achieved the best AUROC of 0.69
178 (95% CI 0.52-0.87) (Figure 2, Supplementary Figure 5, Supplementary Table 4). Importantly, using the Z2
179 threshold as the upper limit of normal range derived from patients with sustained cure 2 years post-treatment,
180 we found most sputum culture-positive individuals at 8 weeks with blood RNA and CRP measurements in the
181 normal range, indicative of the presence of viable bacteria without a discernible host response.

182 We performed three exploratory secondary analyses. First, we reasoned that the magnitude of host-response
183 as reflected by biomarker levels may be quantitatively related to bacterial load. However, among patients who
184 were sputum culture positive at 8 weeks, none of the contemporary biomarker measurements showed a
185 statistically significant correlation with time to culture positivity as a surrogate for bacterial load (Figure 3).
186 Second, we tested the hypotheses that the host response pre-treatment, early resolution of host responses at
187 2 weeks post-treatment initiation or the rate of resolution of host responses on treatment over the first 8 weeks
188 may discriminate sputum culture status at 8 weeks. None of these were evident in our analysis (Supplementary

189 Figure 6-7). Third, we tested the performance of the Darboe11 signature that had previously been reported to
190 provide some discrimination between sputum culture positive and negative cases after 8 weeks treatment
191 among HIV co-infected people with pulmonary tuberculosis¹⁷. Herein, we used the average expression of the
192 genes in this signature which we found to be equivalent to the original support vector machine model as a
193 biomarker of active TB²⁰. The performance of the modified Darboe11 signature was comparable to all other
194 signatures in our analysis. This signature normalised with time on treatment, but did not discriminate sputum
195 culture status or relate to bacterial load at 8 weeks of treatment (Supplementary Figure 8).

Discussion

196 To the best of our knowledge, we report the first evaluation of the resolution of blood RNA biomarkers of TB
197 and CRP as a test of sputum culture conversion to reflect microbiological cure following 8 weeks of
198 antimicrobial treatment for TB. Even though elevated pre-treatment biomarker levels reduced to levels within
199 the pre-specified normal range by 8 weeks of treatment, none of the blood RNA biomarkers showed statistically
200 significant discrimination of contemporary sputum culture status at this time point. CRP achieved marginal
201 albeit statistically significant discrimination. In addition, we found no relationship between contemporary
202 bacterial load and biomarker levels as continuous variables, and no relationship between biomarker levels at
203 earlier time points or their response to treatment with 8-week sputum culture conversion. These results suggest
204 that the current repertoire of blood RNA signatures of TB and CRP will not provide host response surrogates
205 of microbiological cure.

206 Our findings also provide novel biological insights suggesting that the host response may be 'decoupled' from
207 the clearance of *Mtb* from the lung. Importantly, given blood RNA biomarkers can detect pre-symptomatic
208 incipient TB⁸, our data provide the most direct evidence to date for *Mtb* colonisation of the respiratory tract
209 without a discernible host response. This interpretation is further supported by our recent report of detection
210 of *Mtb* DNA in circulating haematopoietic stem cells without perturbation of the blood transcriptome providing
211 bona fide evidence of latent infection²⁴. A possible explanation is that these blood RNA signatures reflect a
212 host response to some *Mtb* subpopulations, rather than all *Mtb*, and that these populations may have
213 differential rates of clearance on starting treatment. Since sputum culture conversion only measures the bacilli
214 that can be expectorated, these two tests may not be measuring the same *Mtb* populations. Testing blood
215 biomarkers against culture conversion, as a proxy for disease activity, may therefore never achieve a test of
216 microbiological cure. Importantly, sputum culture conversion at 8 weeks has not faithfully predicted long term
217 treatment outcomes in clinical trials²⁵. Mycobacterial genetic material has been detected in pulmonary samples
218 long after TB cure, suggesting that residual bacillary material is not exclusively associated with disease²⁶.
219 Therefore, it may be that blood RNA biomarkers at the time of treatment cessation using truncated regimens
220 can predict long term disease relapse even if they cannot predict contemporary microbial sterilisation.

221 Strengths of this study include the use of a comprehensive systematic review to select transcriptional
222 signatures for head-to-head analysis alongside that of CRP. Quantitative bacterial load data from sputum
223 cultures also enabled us to test for continuous relationships between host response and bacterial load. The
224 small sample size of study population is a limitation but does not detract from the observation that normalisation
225 of blood RNA signatures at 8 weeks did not provide an adequate test of *Mtb* clearance from sputum at this
226 timepoint. Some of the reconstructed signatures were incomplete because they contained genes, miRNAs or
227 pseudogenes that were missing in the AdjuVIT dataset. Nonetheless, they achieved comparable accuracies

228 to the complete signatures. Some blood RNA signatures were excluded completely because we were not able
229 to reconstruct them adequately in our data set. However, previous analysis that shows co-correlation of these
230 signatures⁸, suggests that our findings are likely to be generalisable to other blood RNA signature of active
231 TB.

232 In view of the limitations of sputum culture conversion as an end point, future evaluation of these signatures
233 should be undertaken in treatment shortening trials to assess their ability to discriminate patients with and
234 without relapse after the end of treatment. Such studies should continue to incorporate genome-wide
235 transcriptional profiling to support discovery of novel signatures for this application and head-to-head analysis
236 of different signatures as they emerge.

Author contributions

237 MN and ARM conceived the study. CC, ASM, BO performed the systematic review. JR performed the blood
238 transcriptional profiling. CC, ASM, RKG performed the data analysis. CC and MN wrote the paper with input
239 from all the authors.

Funding

240 MN acknowledges support from the Wellcome Trust (207511/Z/17/Z) and NIHR Biomedical Research Funding
241 to UCL and UCLH; RKG acknowledges support from National Institute for Health Research (NIHR302829).
242 ARM acknowledges support from Asthma + Lung UK (ref TB05/11). CJC acknowledges funding from
243 Wellcome Trust (203905/Z/16/Z). BO acknowledges support from an NIHR Academic Clinical Fellowship
244 award.

Declaration of interests

245 JR, MN and ARM hold a patent in relation to blood transcriptomic biomarkers of tuberculosis. All other authors
246 declare no competing interests.


References

- 247 1. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Susceptible Tuberculosis
248 Treatment.; 2022. <https://www.who.int/publications-detail-redirect/9789240048126>. Accessed September
249 25, 2023.
- 250 2. Gelband H. Regimens of less than six months for treating tuberculosis. *Cochrane Database Syst Rev.*
251 2000;(2):CD001362. doi:10.1002/14651858.CD001362.
- 252 3. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJ, Nunn
253 AJ, the REMoxTB Consortium. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive
254 Tuberculosis. *N Engl J Med.* September 2014. doi:10.1056/NEJMoa1407426.
- 255 4. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa
256 F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL,
257 Lienhardt C, OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxacin-containing
258 regimen for treating tuberculosis. *N Engl J Med.* 2014;371(17):1588-1598. doi:10.1056/NEJMoa1315817.
- 259 5. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan
260 HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV,
261 Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E,
262 Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group and the Tuberculosis
263 Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. *N*
264 *Engl J Med.* 2021;384(18):1705-1718. doi:10.1056/NEJMoa2033400.
- 265 6. Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, Tharyan P, Kirubakaran R. Shortened treatment
266 regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. *Cochrane Database*
267 *Syst Rev.* 2019;12(12):CD012918. doi:10.1002/14651858.CD012918.pub2.
- 268 7. Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL,
269 Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin
270 R, Papineni P, Nunn AJ, Crook AM, TRUNCATE-TB Trial Team. Treatment Strategy for Rifampin-
271 Susceptible Tuberculosis. *N Engl J Med.* 2023;388(10):873-887. doi:10.1056/NEJMoa2212537.
- 272 8. Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, Lipman M, Abubakar I, Noursadeghi
273 M. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and
274 patient-level pooled meta-analysis. *Lancet Respir Med.* January 2020. doi:10.1016/S2213-
275 2600(19)30282-6.
- 276 9. Hoang LT, Jain P, Pillay TD, Tolosa-Wright M, Niazi U, Takwoingi Y, Halliday A, Berrocal-Almanza LC,
277 Deeks JJ, Beverley P, Kon OM, Lalvani A. Transcriptomic signatures for diagnosing tuberculosis in clinical
278 practice: a prospective, multicentre cohort study. *Lancet Infect Dis.* 2021;21(3):366-375.
279 doi:10.1016/S1473-3099(20)30928-2.
- 280 10. Mendelsohn SC, Mbandi SK, Fiore-Gartland A, Penn-Nicholson A, Musvosvi M, Mulenga H, Fisher M,
281 Hadley K, Erasmus M, Nombida O, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M, Scriba TJ.
282 Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary
283 tuberculosis by real-time PCR. *Commun Med (London).* 2022;2(1):26. doi:10.1038/s43856-022-00086-
284 8.
- 285 11. Turner CT, Gupta RK, Tsaliki E, Roe JK, Mondal P, Nwayo G, Palmer Z, Miller R, Reeve B, Theron G,
286 Noursadeghi M. Systematic validation of blood transcriptional biomarkers for active pulmonary
287 tuberculosis in a high-burden setting: a prospective diagnostic accuracy study. *Lancet Respiratory*
288 *Medicine.* 2020.
- 289 12. Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, Ronacher K, Tromp G, Tabb DL, Alland
290 D, Shenai S, Via LE, Warwick J, Aderem A, Scriba TJ, Winter J, Walzl G, Zak DE, Catalysis TB-Biomarker
291 Consortium. Host blood RNA signatures predict the outcome of tuberculosis treatment. *Tuberculosis*
292 *(Edinb).* 2017;107:48-58. doi:10.1016/j.tube.2017.08.004.
- 293 13. Tabone O, Verma R, Singhanian A, Chakravarty P, Branchett WJ, Graham CM, Lee J, Trang T, Reynier F,
294 Leissner P, Kaiser K, Rodrigue M, Woltmann G, Haldar P, O'Garra A. Blood transcriptomics reveal the

- 295 evolution and resolution of the immune response in tuberculosis. *Journal of Experimental Medicine*.
296 2021;218(10):e20210915. doi:10.1084/jem.20210915.
- 297 14. Warsinske HC, Rao AM, Moreira FMF, Santos PCP, Liu AB, Scott M, Malherbe ST, Ronacher K, Walzl
298 G, Winter J, Sweeney TE, Croda J, Andrews JR, Khatri P. Assessment of Validity of a Blood-Based 3-
299 Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment
300 Response. *JAMA Netw Open*. 2018;1(6):e183779. doi:10.1001/jamanetworkopen.2018.3779.
- 301 15. Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, Malherbe ST,
302 Darboe F, Erasmus M, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Winter J, Murphy M, Wood R,
303 Morrow C, Van Rhijn I, Moody B, Murray M, Andrade BB, Sterling TR, Sutherland J, Naidoo K, Padayatchi
304 N, Walzl G, Hatherill M, Zak D, Scriba TJ, Adolescent Cohort Study team, GC6-74 Consortium, SATVI
305 Clinical and Laboratory Team, ScreenTB Consortium, AE-TBC Consortium, RePORT Brazil Team,
306 Peruvian Household Contacts Cohort Team, CAPRISA IMPRESS team. RISK6, a 6-gene transcriptomic
307 signature of TB disease risk, diagnosis and treatment response. *Sci Rep*. 2020;10(1):8629.
308 doi:10.1038/s41598-020-65043-8.
- 309 16. Long NP, Phat NK, Yen NTH, Park S, Park Y, Cho Y-S, Shin J-G. A 10-gene biosignature of tuberculosis
310 treatment monitoring and treatment outcome prediction. *Tuberculosis*. 2021;131:102138.
311 doi:10.1016/j.tube.2021.102138.
- 312 17. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, Duffy FJ, Fisher M, Filander E,
313 van Rooyen M, Bilek N, Mabwe S, McKinnon LR, Chegou N, Loxton A, Walzl G, Tromp G, Padayatchi N,
314 Govender D, Hatherill M, Karim SA, Zak DE, Penn-Nicholson A, Scriba TJ, The SATVI Clinical
315 Immunology Team. Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood
316 Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. *Frontiers in*
317 *Microbiology*. 2019;10. <https://www.frontiersin.org/articles/10.3389/fmicb.2019.01441>. Accessed
318 October 18, 2023.
- 319 18. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC,
320 Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Woodward NJ, Venton TR, Barnes KE,
321 Mullett CJ, Coussens AK, Rutterford CM, Mein CA, Davies GR, Wilkinson RJ, Nikolayevskyy V,
322 Drobniowski FA, Eldridge SM, Griffiths CJ. High-dose vitamin D(3) during intensive-phase antimicrobial
323 treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. *Lancet*.
324 2011;377(9761):242-250. doi:10.1016/S0140-6736(10)61889-2.
- 325 19. Calderwood CJ, Reeve BW, Mann T, Palmer Z, Nyawo G, Mishra H, Abubakar I, Noursadeghi M, Theron
326 G, Gupta RK. Clinical utility of C-reactive protein-based triage for presumptive pulmonary tuberculosis in
327 South African adults. *J Infect*. November 2022:S0163-4453(22)00639-9. doi:10.1016/j.jinf.2022.10.041.
- 328 20. Mann T, Gupta RK, Reeve BW, Ndlangalavu G, Chandran A, Krishna AP, Calderwood C, Tshivhula H,
329 Palmer Z, Naidoo S, Mbu DL, Theron G, Noursadeghi M. Blood RNA biomarkers for tuberculosis screening
330 in people living with HIV prior to anti-retroviral therapy initiation: A diagnostic accuracy study. *medRxiv*.
331 January 2023:2023.06.01.23290783. doi:10.1101/2023.06.01.23290783.
- 332 21. Roe JK, Thomas N, Gil E, Best K, Tsaliki E, Morris-Jones S, Stafford S, Simpson N, Witt KD, Chain B,
333 Miller RF, Martineau A, Noursadeghi M. Blood transcriptomic diagnosis of pulmonary and extrapulmonary
334 tuberculosis. *JCI Insight*. 2016;1(16):e87238. doi:10.1172/jci.insight.87238.
- 335 22. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, Timms PM, Venton TR,
336 Bothamley GH, Packe GE, Darmalingam M, Davidson RN, Milburn HJ, Baker LV, Barker RD, Mein CA,
337 Bhaw-Rosun L, Nuamah R, Young DB, Drobniowski FA, Griffiths CJ, Martineau AR. Vitamin D accelerates
338 resolution of inflammatory responses during tuberculosis treatment. *Proceedings of the National*
339 *Academy of Sciences*. 2012;109(38):15449-15454. doi:10.1073/pnas.1200072109.
- 340 23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver
341 operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44(3):837-845.
- 342 24. Rosenheim J, Abebe M, Reece S, Noursadeghi M, Martineau AR. Detection of M. tuberculosis DNA in TB
343 contacts PBMC does not associate with blood RNA signatures for incipient tuberculosis. *medRxiv*.
344 September 2023. doi:10.1101/2023.09.26.23296131.

- 345 25. Phillips PPJ, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH. Limited
346 role of culture conversion for decision-making in individual patient care and for advancing novel regimens
347 to confirmatory clinical trials. **BMC Medicine**. 2016;14(1):19. doi:10.1186/s12916-016-0565-y.
- 348 26. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via
349 LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE, Winter J, Walzl G, Catalysis TB–Biomarker
350 Consortium, Lucas L, Spuy G van der, Stanley K, Theart L, Smith B, Burger N, Beltran CGG, Maasdorp
351 E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Kogelenberg C, Vorster M, Griffith-Richards S.
352 Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after
353 tuberculosis cure. **Nat Med**. September 2016. doi:10.1038/nm.4177.
- 354


Figure 1



355 **Longitudinal blood RNA signature scores by time from start of TB treatment**

356 Blood RNA signature scores standardised to the distribution of 2 year post-treatment samples are shown pre-
 357 treatment, and 2 weeks, 8 weeks and 2 years (2y) from initiation of treatment. 2 week, 8 week and 2 year time
 358 points were compared to pre-treatment by Wilcoxon Rank Sum test. *p values for change from baseline to
 359 timepoint indicated with * p < 0.05, ** p < 0.01 *** p < 0.001 and **** p < 0.0001. Grey shaded area indicates Z-
 360 score +/-2 (normalised to 2-year values).

Figure 2




361 **Blood RNA signature scores and sputum culture status at 8 weeks.**

362 Distributions of blood RNA signature scores at 8 weeks of treatment for tuberculosis, stratified by contemporary
363 sputum culture status, showing AUROC (\pm 95% confidence intervals) for each signature.

364 ...

Figure 3



365 ***Relationship between blood RNA signature and bacterial load at 8weeks***

366 Scatter plot of blood RNA signature scores with sputum culture time (days) to positivity as a surrogate of
367 bacterial load at 8 weeks of TB treatment showing individual data points and linear model (with 95% confidence
368 limits) for sputum culture positive cases.